Tharimmune (THAR) Competitors

BioVie (NASDAQ:BIVI) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Do institutionals & insiders have more ownership in BIVI or THAR?

4.6% of BioVie shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 2.4% of BioVie shares are held by company insiders. Comparatively, 10.0% of Tharimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has more risk & volatility, BIVI or THAR?

BioVie has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.

Is BIVI or THAR more profitable?

BioVie's return on equity of -100.88% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-100.88%	-78.49%
Tharimmune	N/A	-489.33%	-264.34%

Which has better valuation and earnings, BIVI or THAR?

Tharimmune is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$32.12M	-$79.10	-0.09
Tharimmune	N/A	N/A	-$12.20M	-$7.88	-0.22

Do analysts prefer BIVI or THAR?

Tharimmune has a consensus price target of $17.00, indicating a potential upside of 882.66%. Given Tharimmune's higher probable upside, analysts plainly believe Tharimmune is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Tharimmune	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Does the media favor BIVI or THAR?

In the previous week, BioVie had 1 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Tharimmune. Tharimmune's average media sentiment score of 1.89 beat BioVie's score of 1.56 indicating that Tharimmune is being referred to more favorably in the news media.

Company	Overall Sentiment
BioVie	Very Positive
Tharimmune	Very Positive

Summary

Tharimmune beats BioVie on 7 of the 12 factors compared between the two stocks.